TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04536610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing structured osteoporosis education
Description: The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Giving informative leaflet
Description: Leaflets containe the same information as the OP education program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Giving informative leaflet
Description: Leaflets containe the same information as the OP education program
Study: NCT04978142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
Study: NCT01674335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Operant Learning
Description: The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Energy Conservation
Description: The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months.
Study: NCT02550522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton
Study: NCT03902847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Control Exercises
Description: The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
Study: NCT00958620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Therapy
Description: Extracorporal shock-wave therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Shock Wave Therapy
Description: Extracorporal shock-wave therapy
Study: NCT03049735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix (40 mg) tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix (40 mg) tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study: NCT04543604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leatlet + visual aid (pictogram)
Description: The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet + no visual aid (no pictogram)
Description: The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
Study: NCT01439919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR411298
Description: Form: tablet~Route: oral administration with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SSR411298)
Description: Form: tablet~Route: oral administration with food
Study: NCT02628301

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypercaloric diet
Description: Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normocaloric diet
Description: Normocaloric diet
Study: NCT02407366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib (125 mg ,Three times daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed(500mg/m2)every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC，5) every 21 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic radiotherapy(TRT)
Description: TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy(TRT)
Description: TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
Study: NCT02273726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm.
Study: NCT01998126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT04063254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiotherapy
Description: High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
Study: NCT00781820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifonazole cream 1%
Description: 1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: 1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
Study: NCT03040310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back Rx program
Description: The Back Rx program can be viewed via a smartphone app.
Study: NCT03203551

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Disinfection Protocol
Description: The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disinfection Protocol
Description: The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disinfection Protocol
Description: The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disinfection Protocol
Description: The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Study: NCT04311567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Study: NCT00866697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800 mg tablet daily for 104 weeks (24 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Study: NCT00496795

Intervention type: OTHER
Group type: OTHER
Intervention: epirubicin/docetaxel sequential
Description: Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
Study: NCT04312464

Intervention type: OTHER
Intervention: non
Description: no intervention

Intervention type: OTHER
Intervention: non
Description: no intervention
Study: NCT03228758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per Oral Endoscopic Myotomy
Description: The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per Oral Endoscopic Myotomy
Description: The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
Study: NCT03457883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: herniamesh
Description: Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biological graft
Description: Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
Study: NCT02435589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic pain assessment
Description: Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic pain assessment
Description: Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification of results of assessments
Description: Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
Study: NCT01974596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic tablets of Lactobacillus reuteri
Study: NCT01857492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation
Description: Both Active and SHAM groups will receive Meditation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Meditation
Description: Both Active and SHAM groups will receive Meditation.
Study: NCT01974596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Study: NCT02978079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated pupillometry
Description: Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
Study: NCT01428661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily
Study: NCT05425706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of SNAGs technique
Description: in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
Study: NCT02887027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise4Mood Intervention
Description: The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise4Mood Intervention
Description: The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise4Mood Intervention
Description: The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
Study: NCT03002519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-R18
Description: Intramuscular (IM) administration of PLX-R18
Study: NCT03944135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web platform: Neuronup
Description: Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web platform: Neuronup
Description: Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
Study: NCT01563185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen/26.6 mg famotidine
Description: Oral tablet taken three time per day
Study: NCT02049034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lixisenatide
Description: Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
Study: NCT03075072

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation
Description: Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation (SRS)
Description: Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.